These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32645244)

  • 21. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.
    Thompson KM; Kalkowska DA; Badizadegan K
    Risk Anal; 2021 Feb; 41(2):376-386. PubMed ID: 33084153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    Modlin JF; Bandyopadhyay AS; Sutter R
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S398-S404. PubMed ID: 34590135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
    Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
    Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polio Eradication and Endgame Plan - Victory within Grasp.
    Patel M; Menning L; Bhatnagar P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S28-S32. PubMed ID: 27771636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Polio vaccines, eradication and posterradication].
    Salmerón García F; Portela Moreira A; Soler Soneira M; López Hernández S; Chamorro Somoza Díaz-Sarmiento M; Pérez González I; Rubio Gómez MI; Pérez González A; Sagredo Rodríguez A; Ruiz Antúnez S; Timón Jiménez M; Frutos Cabanillas G
    Rev Esp Salud Publica; 2013; 87(5):497-505. PubMed ID: 24322286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.
    Duintjer Tebbens RJ; Pallansch MA; Wassilak SG; Cochi SL; Thompson KM
    BMC Infect Dis; 2016 Mar; 16():137. PubMed ID: 27009272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization.
    Thompson KM; Kalkowska DA; Kidd SE; Burns CC; Badizadegan K
    Vaccine; 2024 Feb; 42(4):819-827. PubMed ID: 38218668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.
    Badizadegan K; Kalkowska DA; Thompson KM
    Med Decis Making; 2023; 43(7-8):850-862. PubMed ID: 37577803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036.
    Thompson KM; Kalkowska DA; Badizadegan K
    Expert Rev Vaccines; 2022 Nov; 21(11):1667-1674. PubMed ID: 36154436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
    Thompson KM; Kalkowska DA; Badizadegan K
    Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.